DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
BlueRock - 2 Britain's - 2 Ludwig Burger - 2 Christian Rommel - 1 Bayer's - 1 Susan Fenton - 1 Wolfgang Rattay - 1 Bayer - 1
Top related locs:
Australia Copenhagen Denmark United States Leverkusen Germany FRANKFURT San Francisco Bay
Top related orgs:
Bayer - 2 Cambridge University - 2 South Korea's - 2 CHA Hospital - 2 Cyto Therapeutics - 2 Chinese Academy of Sciences - 2 Harvard University - 2 Japan's Kyoto University Hospital - 2

Search resuls for: "Cyto Therapeutics"


2 mentions found


☆ Bayer says Parkinson's stem cell therapy improves symptoms in initial trial
  + stars: | 2023-08-28 | by ( Ludwig Burger | ) www.reuters.com   time to read: +3 min
FRANKFURT, Aug 28 (Reuters) - Bayer (BAYGn.DE) said an experimental stem cell therapy developed by its U.S. subsidiary BlueRock had shown signs of easing Parkinson’s disease symptoms in an early 12-patient trial. The German drugmaker announced the trial had succeeded in a brief summary in June, saying it was a first for a stem-cell Parkinson's therapy, but held back details for a medical conference. The five participants on a lower dose experienced 0.72 hours longer per day with well-controlled symptoms on average and the time of worsening symptoms was 0.75 hours shorter per day for them. For BlueRock's experimental therapy, the researchers took human pluripotent embryonic stem cells and transformed them into dopamine-producing nerve cells. Parkinson's, for which there is no cure and which affects more than 10 million people worldwide, causes progressive brain damage.
Persons: BlueRock, Christian Rommel, Bayer's, Britain's, Ludwig Burger, Susan Fenton Organizations: FRANKFURT, Bayer, U.S, drugmaker, International Congress, Cambridge University, South Korea's, CHA Hospital, Cyto Therapeutics, Chinese Academy of Sciences, Harvard University, Japan's Kyoto University Hospital, Thomson Locations: Copenhagen, Denmark, Australia, United States
☆ Bayer claims early lead in Parkinson's stem cell therapy
  + stars: | 2023-06-28 | by ( Ludwig Burger | ) www.reuters.com   time to read: +3 min
Some of this work is done by Britain's' Cambridge University, South Korea's Bundang CHA Hospital, International Stem Cell Corp's (ISCO.PK) Cyto Therapeutics in Australia, the Chinese Academy of Sciences, Harvard University and Japan's Kyoto University Hospital. For BlueRock's experimental therapy, researchers took induced pluripotent stem cells, which are modified to regain the ability to form any type of specialised tissue, and transformed them into dopamine-producing nerve cells. When surgically implanted into the brain of a person with Parkinson's disease, the therapeutic cells are designed to restore neural networks destroyed by the disease. Initial trial results showed the cells multiplied and started making dopamine, an important brain signalling molecule which is lacking in Parkinson's patients. Parkinson's, for which there is no cure and which affects more than 10 million people worldwide, causes progressive brain damage.
Persons: Wolfgang Rattay, Bayer, BlueRock, Britain's, Jennifer Doudna, Ludwig Burger, Miranda Murray, Mark Potter Organizations: Bayer AG, REUTERS, Bayer, Cambridge University, South Korea's, CHA Hospital, Cyto Therapeutics, Chinese Academy of Sciences, Harvard University, Japan's Kyoto University Hospital, BlueRock Therapeutics, Mammoth Biosciences, Thomson Locations: Leverkusen, Germany, FRANKFURT, Australia, San Francisco Bay
0 next >>
Total: 2